A Study of Brenipatide in Participants With Alcohol Use Disorder

Inclusion Criteria:

• Participant must be a minimum of 20 years of age for the investigative sites inJapan.

• Are seeking treatment and are motivated to stop or cut down on drinking.

• Are reliable and willing to make themselves available for the duration of the studyand attend required study visits, and are willing and able to follow studyprocedures as required, such as

• self-inject study intervention Note: Participants who are not able to performthe injections must receive assistance from a support person trained toadminister the study intervention.

• store and use the provided blinded study intervention, as directed

• maintain electronic and paper study diaries, as applicable, and

• complete the required questionnaires.

Exclusion Criteria:

• Have evidence of current or within the past 180 days prior to screening (V1),history of any substance use disorder(s) of any severity with a pattern ofpersistent illicit or nonprescribed substance use as indicated by clinicalinterview, except alcohol, nicotine, or caffeine.

• Have answered "yes" to either Question 4 or Question 5 on the "Suicidal Ideation"portion of the Columbia-Suicide Severity Rating Scale (C-SSRS) and the ideationoccurred within the past 6 months, or Have answered "yes" to any of thesuicide-related behaviors on the "Suicidal Behavior" portion of the C-SSRS and thebehavior occurred within the past 6 months

• Have a history of advanced liver disease (including advanced liver fibrosis orcirrhosis), or alcohol associated hepatitis based on either prior liver histology orimaging studies, such as transient elastography, ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI), or Enhanced Liver Fibrosis score.

• Have participated in a clinical study and have received active treatment, or unknownif they received active treatment, within 90 days or 5 half-lives (whichever islonger) before screening (V1).